2016 Hematological Malignancies

Previous Page

Next Page

Page Background

Simon‘s two stage

Optimal

design (α=0.05):



H0: ARR <5%



will be rejected with 95% power if real ARR is ≥30%

Nivo

RE-Staging 1

POD: biopsy

Nivo

Nivo Nivo

RT 20Gy

w1d4-w3d2

Nivo

Nivo

relapsed/refractory cHL

anti-PD1 pretreated

Nivo

Nivo Nivo Nivo Nivo

Nivo

PET-Staging 2

POD: biopsy

w1d1

w3d1 w5d1 w7d1 w9d1 w11d1 w12

w24

Abscopal Phase II Study

Flowchart